Compare JetBlue Airways Corporation (JBLU) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JetBlue Airways Corporation vs Eli Lilly And Co — how do they compare? JetBlue Airways Corporation trades at $3.88 (market cap $1.48B), while Eli Lilly And Co trades at $1,168.25 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 702.7× JetBlue Airways Corporation's market cap, and Eli Lilly And Co pays a 0.59% dividend while JetBlue Airways Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold JetBlue Airways Corporation for 44 Days and Eli Lilly And Co for 93 Days on average.
| JBLU | LLY | |
|---|---|---|
Market Cap | $1.48B | $1.04T |
Volume | 30,275,693 | 3,064,878 |
Sector | Industrials | Health |
52-Week High | $6.46 | $1.28K |
52-Week Low | $3.92 | $799.57 |
Typical Hold Time | 44 Days | 93 Days |
Enterprise Value | $8.84B | $1.09T |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JetBlue (JBLU) trades at $3.97, down 1.49% on the day, with the stock showing bearish technical momentum despite trading near its 52-week low. The company continues to face fundamental challenges with negative net income margins (-9.32% in 2025) and declining revenue trends, though valuation metrics like P/S (0.15) and P/B (0.94) appear attractive. Recent developments include route expansion to Colombia and the launch of BlueFirst premium seating, while activist investor Carl Icahn recently exited board positions per the 2024 agreement.
The outlook remains challenging with persistent losses and high debt levels (debt-to-asset ratio over 50%), though analyst consensus targets $5.89 suggesting potential upside. Key risks include elevated fuel costs, competitive pressures, and ongoing negative cash flow from operations. Investment opportunity exists for value investors betting on operational turnaround, but requires careful risk management given the company's financial strain.
Eli Lilly (LLY) trades at $1,188.72, up 2.7% on the day, with a bullish technical signal and strong fundamentals. Recent earnings beats, robust revenue growth to $65.18B in 2025, and a net income margin of 33.53% highlight operational strength. Positive news flow centers on next-generation weight-loss drugs, with analyst consensus bullish and a price target of $1,350.
Outlook remains positive given pipeline catalysts in obesity/diabetes markets, though high valuations (P/E 39.9) and rising debt levels pose risks. Competitive intensity and regulatory scrutiny are watchpoints, but institutional support and earnings momentum underpin further upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
